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Summary
Hepatocellular carcinoma (HCC) is an aggressive malignancy mainly due to metastases or postsurgical recurrence. We
postulate that metastases are influenced by the liver microenvironment. Here, we show that a unique inflammation/immune
response-related signature is associated with noncancerous hepatic tissues from metastatic HCC patients. This signature
is principally different from that of the tumor. A global Th1/Th2-like cytokine shift in the venous metastasis-associated liver
microenvironment coincides with elevated expression of macrophage colony-stimulating factor (CSF1). Moreover, a refined
17 gene signature was validated as a superior predictor of HCC venous metastases in an independent cohort, when
compared to other clinical prognostic parameters. We suggest that a predominant humoral cytokine profile occurs in
the metastatic liver milieu and that a shift toward anti-inflammatory/immune-suppressive responses may promote HCC
metastases.Introduction
Cancer metastasis is a complex multistep process that involves
alterations in dissemination, invasion, survival, and growth of
new cancer cell colonies and the development of cancer-asso-
ciated vasculature (Hanahan andWeinberg, 2000; Liotta, 1985).
Recently, the traditional metastasis paradigm has been chal-
lenged by the observations that most of the genetic and epige-
netic changes necessary for metastasis appear to be the hall-
marks of cancer (Bernards and Weinberg, 2002; Hanahan and
Weinberg, 2000). For example, the molecular signature in pri-
mary tumors from gene expression profiling studies predict can-
cer patient metastasis and survival (Ramaswamy et al., 2003;
van de Vijver et al., 2002; Ye et al., 2003). Since microarrays de-
tect signals contributed by the bulk of the tissues examined, theCANCER CELL 10, 99–111, AUGUST 2006 ª2006 ELSEVIER INC. DOI 1results suggest that a majority of primary tumor cells have
acquired changes that favor metastasis. Interestingly, despite
the significant and continuous tumor cell dissemination into
the circulation in cancer patients, clinical observation and ani-
mal model studies indicate that metastasis is a rather inefficient
process (Fidler and Kripke, 2003). This raises a debate as to
whether the tendency to metastasize is largely determined by
the identities of mutant alleles acquired relatively early during
multistep tumorigenesis or a potential contribution from host
genetic backgrounds where the local microenvironment of me-
tastasis-susceptible sites may dictate the ability of a tumor to
metastasize, or both (Bernards and Weinberg, 2002; Fidler,
1995; Hunter, 2004).
Hepatocellular carcinoma (HCC) represents an extremely
poor prognostic cancer (Thorgeirsson and Grisham, 2002).S I G N I F I C A N C E
The poor outcome of HCC patients results frommetastases and/or postsurgical recurrence of the primary tumor. Despite considerable
tumor cell dissemination, frequently observed in the hepatic venous system,metastases are rare andmay be influencedby permissive
target environments. Here, we demonstrate that significant gene expression changes occur in the liver microenvironment of patients
with accompanying venous metastases. We reveal a unique expression signature, largely contributed by inflammation/immune re-
sponses, in noncancerous hepatic tissues with venous metastasis. This signature is a superior predictive tool to determine HCC venous
metastases and relapse and may have possible utility in clinical settings to identify HCC patients who may benefit from certain post-
surgical treatment to prevent metastases and/or recurrence.0.1016/j.ccr.2006.06.016 99
A R T I C L EThe dismal outcome has been attributed to the highly vascu-
lar nature of HCC tumors, which increases the propensity to
spread and invade into neighboring or distant sites (Nakakura
and Choti, 2000; Tang, 2001). Intrahepatic metastases, espe-
cially venous metastases, are a major hallmark of metastatic
HCC, with new tumor colonies frequently invading into the
major branches of the portal vein or, to a lesser extent, the
inferior vena cava and possibly other parts of the liver (Yuki
et al., 1990). Another feature of HCC is a high frequency of
multiple nodules that occur in the same or different lobes.
Many of these lesions can be multicentric, resulting from mul-
tiple de novo tumors, and thus may not be metastases. Re-
cently, we developed a gene expression signature specific
to primary HCC specimens to predict prognosis and venous
metastases (Ye et al., 2003). The tumor signature provided
78% overall accuracy in predicting HCC patients with meta-
static potential. The presence of a prognostic signature in pri-
mary HCC specimens was confirmed by several studies (Ii-
zuka et al., 2003; Lee et al., 2004). However, HCC is usually
present in inflamed fibrotic and/or cirrhotic liver with extensive
lymphocyte infiltration due to chronic hepatitis. Thus, it is
possible that HCC metastatic propensity may be determined
and/or influenced by the local tissue microenvironment of
the host.
To determine the role of the hepatic microenvironment in
HCC metastasis, we compared the gene expression profiles
of 115 noncancerous surrounding hepatic tissues from two
HCC patient groups, those with primary HCC with venous me-
tastases (major branch of the portal vein or inferior vena cava)
or confirmed extrahepatic metastases by follow-up, which we
termed a metastasis-inclined microenvironment (MIM) sample,
and those with HCC without detectable metastases, which we
termed a metastasis-averse microenvironment (MAM) sample.
Using this patient cohort, we first conducted gene expression
profiling studies of a subset of MIM and MAM samples using
cDNA microarray. We identified a unique change in the gene
expression profiles associated with a metastatic phenotype.
Furthermore, using the same subset of MIM and MAM samples
used in the microarray, we constructed a refined expression
signature containing 17 genes, which we determined by quan-
titative real-time polymerase chain reaction analyses (qRT-
PCR). This signature was validated by an independent cohort
of 95 MIM and MAM samples and could successfully predict
both venous metastases and extrahepatic metastases by fol-
low-up with >92% overall accuracy. Moreover, the prognostic
performance of this signature was superior to and independent
of other available clinical parameters for determining patient
survival or recurrence including patient age, tumor size, liver
function, microvascular invasion, TNM staging, etc. Analysis
of the lead signature genes revealed their involvement in the
cellular immune and inflammatory responses. Consistently,
dramatic changes in cytokine responses, favoring an anti-
inflammatory microenvironmental condition, occur in MIM sam-
ples, where a predominant Th2-like cytokine profile, favoring
a humoral response, is associated with the MIM condition.
CSF1 may be one of the cytokines overexpressed in the liver
milieu that is responsible for this shift. We suggest that the in-
flammatory status of the surrounding tumor milieu, in addition
to the metastatic potential of the tumor cells, may play an im-
portant role in promoting HCC tumor progression and venous
metastases.100Results
The search for a metastasis signature in noncancerous
hepatic tissue from HCC patients with intrahepatic
venous metastases
We recently developed a metastasis signature based on the
gene expression of primary HCC tumor specimens to predict
metastatic HCC and prognosis with an overall accuracy of
78% (Ye et al., 2003). To analyze a potential contributing role
of the liver microenvironment in promoting intrahepatic venous
metastasis, we first compared the gene expression profiles of
noncancerous hepatic tissues of the cases described above (9
MIM and 11 MAM samples), to a pool of eight disease-free nor-
mal livers utilizing the samemicroarray platform employed in our
previous study (Ye et al., 2003). This approach allowed us to
compare the gene expression between the primary tumor and
its surrounding tissue. Using a supervised class comparison
method at a significance level of p < 0.001, we identified 454 sig-
nificant genes that can discriminate the MIM and MAM groups
(Table S1, ‘‘Training set’’), with a 90% probability of the first
415 genes containing no more than ten false discoveries (Table
S2). We further confirmed these findings by applying a multivar-
iate class prediction algorithm termed compound covariate
predictor (CCP), with leave-one-out cross-validation and 2000
random permutations of the class label. CCP analysis was
statistically significant (p = 0.04) in predicting these samples
with 80% overall accuracy, and similar results were obtained
with four additional algorithms (Table S3). Interestingly, when
comparing this 454 gene signature to a 201 genemetastasis sig-
nature identified from tumor specimens of the same patients at
a lesser significance level (p < 0.002), we found only four over-
lapping genes (VAMP3, PDK1, SLC20A2, and RAB28). These
results indicate that the liver microenvironment signature is prin-
cipally different from the tumor signature. Consistent with our
previous data (Ye et al., 2003), the distinction found in noncan-
cerous hepatic tissues between metastatic and nonmetastatic
patients is also unlikely due to tumor burden because the aver-
age tumor size in the MIM group is similar to that of the MAM
group (Table S4). It has been indicated that microvascular
invasion (the presence of tumor cells inside the lumen of the
microvasculature) may also be associated with poor prognosis.
Interestingly, when we stratified these samples based on the
presence or absence of microvascular invasion, we found only
three significant genes (p < 0.001), and the results of class
prediction were statistically insignificant. At such a significance
level, these genes are likely false positives. Similarly, no differ-
ence in gene expression could be found when the tumor ex-
pression microarray data were used. Thus, it appears that a
significant discriminatory weight can be found with venous
metastases but not with microvascular invasion by the microar-
ray-based expression profiling approach.
A hierarchical clustering of the 454 significant genes revealed
that 295 genes were more abundantly expressed in MIM sam-
ples, while 159 genes were more abundantly expressed in
MAM samples (Figure 1A). A close examination revealed two
striking gene clusters that most significantly differentiated MIM
from MAM samples. We named these two clusters inflamma-
tion/immune response cluster A and B, respectively. Cluster A
contains 38 underexpressed genes, while cluster B contains
68 overexpressed genes in the MIM group. Strikingly, over
30% of the genes in these two clusters have gene annotationsCANCER CELL AUGUST 2006
A R T I C L Eassociated with either inflammation and/or immune response
functions (Figure 1A). For example, HLA-DRA, a MHC class II
molecule, was most significantly upregulated in noncancerous
MIM samples. Another MHC class II molecule, HLA-DPA1,
was also highly upregulated in MIM samples.
To validate the expression level of differential genes in these
samples, we selected HLA-DRA and HLA-DPA1, along with
two mast cell-related genes, PRG1 and ANXA1 (an anti-inflam-
matory protein), represented in Cluster B, to perform qRT-PCR
(Figure 1B), based on their involvement in immunity. The
qRT-PCR analysis demonstrated that these four genes were
significantly upregulated in noncancerous tissues from MIM
compared to MAM samples (Figure 1B). A comparison of the
expression ratios of these four genes from either microarray
analysis or qRT-PCR showed a statistically significant correla-
tion (p < 0.0001; r2 = 0.6187) (Figure 1C). It appears that the
components of the immune system may function as affecting
targets of metastatic potential, and thus, this process may be
influenced by the immune status of hepatic tissues.
HCC venous metastases are accompanied by changes
in the immune status of the tumor-surrounding
tissue microenvironment
Since the immune status of the liver microenvironment seemed
to be associatedwith venousmetastases, we next examined the
status of cellular inflammation by determining the expression of
an inflammatory status marker, nitric oxide synthase 2 (NOS2),
using immunohistochemistry (IHC) analyses of 37 MIM and 31
MAM samples, most of which were not used in our gene expres-
sion profiling studies. NOS2 was detected in noncancerous liver
parenchyma and was mainly contributed by hepatocytes
(Figure 2A). It was evident that NOS2 staining was significantly
different (p = 0.009) between MIM and MAM samples, whereby
nonmetastatic liver parenchyma showed increased expression
of NOS2 (Figure 2B). Since 96% of the samples (65/68) were
from HBV-positive carriers and a majority of them (93%) (63/
68) had underlying cirrhosis by histological evaluation, it was
anticipated that the level of NOS2 would be elevated in these
samples. Thus, it appears that a pro-inflammatory condition is
associated with MAM samples and an anti-inflammatory condi-
tion is associated with MIM samples. However, there is no sig-
nificant difference (p = 0.570) between the overall inflammation
status of benign MIM and MAM tissues based on histological
activity index (Figure S1).
We then determined whether the differences in NOS2 expres-
sion were associated with changes in certain immune cell re-
sponses in MIM samples. We randomly selected ten paraffin-
embeddedMIMorMAMcases, which were subjected to a panel
of immunecellmarkersby IHCanalyses.CD68wasused tomon-
itor the abundance of resident macrophages, the Kupffer cells
(one type of antigen presenting cell [APC]); HLA-DR was used
to determine the activity of APC; CD45 was used to determine
the total leukocyte amount; andCD4 or CD8was used to identify
the number of CD4+ or CD8+ T lymphocytes, respectively. We
found a substantial increase in the numbers of CD68+ and
HLA-DR+ cells in noncancerous liver parenchyma (away from
the portal tract) in patients with metastatic HCC (Figures 2A,
2C, and 2D). All of the CD68+ and HLA-DR+ cells were localized
to the liver sinusoid (Figure 2A), the main site of Kupffer cells;
liver-associated lymphocytes; and liver sinusoidal endothelial
cells. There is a significant correlation in staining betweenCANCER CELL AUGUST 2006CD68 and HLA-DR among these cases (Figure 2E; p = 0.0003;
r2 = 0.5285), indicating that the difference between MIM and
MAM samples is unlikely due to a sampling bias in the staining
area used for quantitation. Interestingly, most of the HLA-DR+
cells appear to overlap with CD68+ cells in MAM samples, while
many more HLA-DR+ cells were evident in MIM samples when
compared to CD68+ cells (Figures 2A and 2E; Figure S2), sug-
gesting that many of the HLA-DR+ cells are contributed by an
APCcell type other thanKupffer cells.Most of theHLA-DR+cells
appear to overlap with CD45+ cells in MIM samples, suggesting
that the microarray-identified HLA-DRA signal is mainly contrib-
uted by leukocytes (Figure S3). The number of CD4+ andCD8+ T
cells ismuch lower in the areaswhereHLA-DR+andCD68+cells
are found, and they are mainly localized in the portal tract where
extensively circulating infiltrating lymphocytes can be found
(data not shown). In addition, we also examined the expression
of CSF1, amajor cytokine regulating the activity of tissuemacro-
phages (Pixley and Stanley, 2004). Similar to NOS2, CSF1 stain-
ing is mainly confined to hepatocytes of noncancerous liver
parenchyma, which can be detected more frequently in MIM
compared to MAM samples with a borderline statistical signifi-
cance (p=0.078) (Figure 2FandFigureS3). A significant increase
in the abundance of CSF1 mRNA in MIM samples (p < 0.0003)
was confirmed by qRT-PCR analysis of noncancerous liver tis-
sues of the original 9 MIM and 11 MAM samples (Figure 2G). It
is plausible that the increase in HLA-DR+ cells, accompanied
by the increase in Kupffer cells, may be due, in part, to an eleva-
tion of CSF1.
The MIM group is associated with an increase in Th2
cytokines and a decrease in Th1 cytokines
Our gene expression results showed a distinct effect on immune
and inflammatory responses in MIM samples, which were cor-
roborated by IHC analysis showing an increase in liver macro-
phages and a decrease in NOS2 expression in samples belong-
ing to this group. Pro-inflammatory cytokines, such as IL1, TNFa
(TNF), and IFNg (IFNG) have also been shown to induce NOS2
expression (Paludan et al., 2001; Spirli et al., 2003). Conse-
quently, we analyzed the cytokine profile of the 9 MIM and 11
MAMsamplesused in themicroarray analysis byqRT-PCRusing
the Taqman Cytokine Gene Expression Plate, composed of 12
cytokines belonging to either Th1 or Th2 families. Strikingly,
MIM samples showed a profound switch in their cytokine pro-
files, with a significant increase in IL4, IL5, IL8, and IL10 (Th2 cy-
tokines) and a concomitant decrease in IL1A, IL1B, IL2, IFNG,
andTNF (Th1 cytokines) compared to anormal liver pool (Figures
3A and 3F). However, such a switch was not evident in MAM
samples, where the profiles were similar to cirrhosis liver sam-
ples from chronic HBV carriers, primary biliary cirrhosis (PBC),
or autoimmune hepatitis (AIH) (Figures 3B–3E). Thus, such a pro-
found cytokine profile switch is unique to hepatic tissues from
metastatic HCCpatients and is unlikely due to the degree of viral
hepatitis or the status of cirrhosis as evidenced by the lack of this
profile in HBV, AIH, or PBC samples, nor is it a consequence of
tumor burden since this profile is not observed in HBV-positive
MAM samples. The observed induction of inflammatory cyto-
kines in MAM samples, such as IFNG and TNF, is consistent
with an increaseof inflammation asevidencedbyNOS2andsug-
gests that the inflammatory status of the liver microenvironment
may retard venousmetastases. Taken together, thesedata imply101
A R T I C L EFigure 1. Significant differentially expressed genes in noncancerous hepatic tissues from MIM and MAM patients
A:Hierarchical clustering of 454 genes whose expression was significantly (p < 0.001) altered in the metastatic (MIM) samples (n = 9) and nonmetastatic (MAM)
samples (n = 11) from class prediction analysis with six different algorithms employing leave-one-out cross-validation to establish prediction accuracy. Each
row represents an individual gene, and each column represents an individual tissue sample. Genes were ordered by Euclidian distance and complete linkage
according to the ratios of abundance in each tissue sample compared to a normal tissue pool (n = 8), which were normalized to the mean abundance of102 CANCER CELL AUGUST 2006
A R T I C L EFigure 2. Metastatic potential is associated with
changes in immune cell expression and inflam-
matory status
A: Five micrometer sections of paraffin-embed-
ded hepatic tissues from a representative MIM
and a MAM case immunostained for NOS2,
HLA-DR, CD68, or H&E are shown. Boxes in the
right corner show magnified images (magnifica-
tion 35). The horizontal black bar represents
50 mm. B: NOS2 staining was quantified for origi-
nal samples and an additional cohort of HCC
samples (MIM: n = 37, MAM: n = 31) based on
blinded-histological scoring determined by
both the intensity and distribution of NOS2 ex-
pression. Quantitation of HLA-DR (C) or CD68
(D) was based on ten randomly selected MIM
or MAM samples with marker expression in liver
parenchymal regions without inflamed regions
such as the portal tract and central vein. Data
(B and D) are shown as the mean 6 SEM, and
the statistical significance was calculated from
the Student’s t test between MIM and MAM sam-
ples. E: Pearson correlation analysis of HLA-DR
versus CD68 staining. F: CSF1 staining was quan-
tified in a similar fashion to NOS2 described
above. G: qRT-PCR of CSF1 was performed as
described in Figure 1B.that an anti-inflammatory status occurs in patients with meta-
static HCC.
To determine if such a profound switch in Th1-Th2 cytokine
profiles was contributed by an abnormal expression of CSF1,
we first examined the serum concentration of CSF1 in an inde-
pendent cohort of 57 patients (10 noncancerous [NC], 33 MAMCANCER CELL AUGUST 2006samples, and 14 MIM) by ELISA. NC samples were cancer-free
HBsAg carriers, defined as patients collected from the same re-
gion as theHCCcaseswithout any detectable tumors at the time
of sample collection. Although MAM samples showed a signifi-
cant elevation of serum CSF1 when compared to NC samples
(p < 0.02), the level of CSF1 is significantly higher inMIMsamplesgenes. Pseudocolors indicate transcript levels below, equal to, or above the mean (green, black, and red, respectively). Missing data are denoted in gray.
The scale represents the gene expression ratios from 2 to22 in log 2 scale. Inflammation/immune response clusters are denoted by the vertical orange bars.
Genes known to be related to the immune and inflammation responses are denoted by the red stars.
B: qRT-PCR validation of significant differentially expressed genes. Relative expression fold of each gene (n = 4) normalized to 18S and a normal tissue pool is
shown forHLA-DRA,HLA-DPA1,ANXA1, and PRG1. Data are presented as the mean6 SEM, and the statistical significance calculated from the Student’s t test
between MIM and MAM samples is shown.
C: Pearson correlation analysis between microarray and qRT-PCR ratios of abundance data for the four validated genes described in B is shown.103
A R T I C L EFigure 3. Metastatic potential is associated with a reprogramming of Th1 and Th2 cytokines in noncancerous hepatic tissues
The cytokine expression profiles of MIM (A), MAM (B), HBV (C), PBC (D), AIH (E), and normal liver (F) samples are shown. qRT-PCR was conducted using the
Taqman Cytokine Gene Expression plate (Applied Biosystems, Foster City, CA). The natural log value of cytokine quantity, normalized to 18S rRNA and to a nor-
mal liver tissue pool (n = 8), is presented as the mean6 SD (standard deviation). Statistically insignificant changes calculated by the Student’s t test (p > 0.05)
relative to normal liver are denoted by asterisks.G–I:CSF1 is more abundant in serum from metastasis patients and can modulate the expression of Th1 and Th2
cytokines, correlating with metastasis cytokine profiles. G: ELISA-based quantitation of the level of CSF1 in human serum from normal liver, MAM, or MIM. Data
are presented as the mean6 SEM, and the statistical significance calculated by a nonparametric test (Mann-Whitney test) among samples is shown. H: The
cytokine expression profiles of peripheral blood mononuclear cells (PBMC) isolated from buffy coat and treated with CSF1 (2 ng/ml), CSF1 blocking antibody
(30 ng/ml), or IL2 (50U) (I) are shown. H and I: Cytokine quantity, normalized to 18S rRNA and BSA treatment, is presented as the mean in log 2 scale of abun-
dance6 SD (n = 3). J:Human PBMC (23 106 cells) was treated with CSF1 (2 ng/ml) for 24 hr followed by treatment with PMA (25 ng/ml) and Calcium Ionophore
(1 mg/ml) for 2 hr and GolgiPLUG (BrefeldinA) for 2 hr. Cells were harvested, stained with FITC-CD3, fixed, permeabilized, treated with serum, and subsequently
stained for the intracellular cytokines APC-IL4 or APC-IFNG. The percentage of cells in each quadrant are shown.(p < 0.002), and the difference between MIM and MAM samples
is evident (p < 0.05) (Figure 3G). The average serum concentra-
tions of CSF1 are 40.76 5.1 pg/ml inNC (6SEM; standard error),104124.6 6 28.9 pg/ml in MAM, and 207.5 6 70.0 pg/ml in MIM,
respectively. Next, to determine the effect of CSF1 on cyto-
kine profiles, we utilized peripheral blood mononuclear cellsCANCER CELL AUGUST 2006
A R T I C L E(PBMC) isolated from healthy donors as a model system, an
immune cell-enriched source to mimic the immune response in
hepatic tissue. We found that, similar to the effect seen in MIM
samples, PBMC incubated with recombinant CSF1 in a physio-
logically relevant concentration resulted in a significant increase
in Th2 and a decrease in Th1 cytokines (Figure 3H). As a control,
recombinant IL2 led to an increase in all cytokines (Figure 3I). The
CSF1 effect canbe observed inPBMC fromat least three healthy
donors tested and is specific to CSF1 since its activity can be
effectively reduced by a CSF1 neutralizing antibody. To address
the cell type affected by CSF1 to induce the cytokine profile shift
noted above, we determined the intracellular concentration of
IL4 and IFNG by fluorescence-activated cell sorting (FACs)
(Figure 3J). We found that, in cells labeled with CD3, a cell sur-
face marker for T cells, CSF1 increased the amount of the Th2
cytokine IL4 by 30% and reduced the levels of the TH1 cytokine
IFNG by 30%. It should be noted that a small fraction of CD3-
negative cells also apparently induce a shift toward Th2 in the
presence of CSF1.
Composition and predictive value of a refined venous
metastasis signature using noncancerous hepatic
tissues
Our results thus far showed that 454 genes could distinguish
MIM andMAM samples by microarray, and a significant amount
of these genes were related to the immune/inflammatory re-
sponse. However, we were inclined to accurately differentiate
these samples using a smaller, more defined set of genes and
a more rapid profiling methodology, namely qRT-PCR, for po-
tential clinical utilization. Consistently, qRT-PCR profiling of 9
MIMand11MAMsamples used in themicroarray study revealed
that 17 immune/inflammatory related genes,whichwe refer to as
the refined liver microenvironment venous metastasis signature
(12 Th1/Th2 cytokines, HLA-DR, HLA-DPA, ANXA1, PRG1, and
CSF1), were sufficient to discriminate MIM from MAM samples
(Figure 4A; Table 1). Hierarchical clustering of 9 MIM, 11 MAM,
and 8 normal liver samples based on the expression of these
17 genes by qRT-PCR resulted in a clear separation of these
three groups, withMIM showing amore dramatic expression dif-
ference when compared to MAM and normal liver samples
(Figure 4A). Thus, these17genesmayprovide auniquesignature
to classify patients with venous metastases by examining only
noncancerous liver tissues (Table 1).
To analyze the prediction accuracy of this 17 gene signature,
we first tested the probability of correctly classifying the original
9 MIM and 11 MAM samples as a training set by the prediction
analysis of microarrays (PAM) algorithm. PAM analysis, utilizing
nearest shrunken centroid classification with 10-fold cross-vali-
dation, resulted in 100% correct classification of these samples
into either theMIM orMAMgroup (Figure 4B). To further validate
our results, we performed qRT-PCR of the 17 gene signature set
on a testing cohort comprised of an additional 95 noncancerous
liver specimens (43 MIM and 52 MAM) (Table S1, ‘‘Testing set’’).
These independent samples had similar clinical profiles as the
original 20 samples used in training, except for some differences
in tumor morphology scores (Table S1). The MIM testing cohort
was comprised of 21 samples with metastases found in the por-
tal vein (n = 30), inferior vena cava (n = 6), or common bile duct
(n = 5) at the time of sample collection, and 11 samples with ex-
trahepatic metastases confirmed by follow-up, of which 10 also
had intrahepatic metastases. Prediction analysis revealed thatCANCER CELL AUGUST 2006the 17 gene signature correctly predicted 38 of 43 MIM cases
(88%) and 49 of 52 MAM cases (94%) (Figure 4C). Importantly,
this signature was capable of accurately predicting 7 of 11
MIM cases (64%) where venous metastases were not present
at the time of sample collection but developed at follow-up. To
further test if there was any grouping bias in training and testing,
we performed PAM analysis with 10-fold cross-validation for all
115 cases. Consistently, this analysis resulted in a 93% overall
correct classification with eight misclassified cases (data not
shown). A close examination of the clinical characteristics of
the eight misclassified cases (three MAM and five MIM) did not
reveal any reason for misclassification (Table S5). In addition,
the 17gene signaturewas anexcellent predictor of patient recur-
rence within this cohort (79% sensitivity and 67% specificity). It
should be noted that, among the 115HCCcases, 99%had a his-
tory of HBV infection and a majority were chronic HBV carriers
(Table S6). In addition, the number of cases with a marker of
active viral replication (HBeAg+) was similar betweenmetastatic
and nonmetastatic groups (Table S6). Thus, it appears that HBV
viral load does not seem to contribute to themetastatic changes
in the local hepatic microenvironment.
To determine if the signature was related to patient prognosis,
we performed Kaplan-Meier survival or recurrence analysis
based on the 17 gene prediction results (Figure 4D). It appeared
that the predicted metastatic group had a significantly shorter
survival period when compared to the nonmetastatic group (p =
4.2e-11). Kaplan-Meier analysis also showed that the predicted
metastatic group had a significantly shorter period for recur-
rence than the nonmetastatic group (Figure 4D; p = 0.0002).
Thus, this signature provides weight to predict both survival
and recurrence. As shown by multidimensional scaling analysis,
samples from theMIM group clustered separately from samples
without venous metastases demonstrating measurable differ-
ences between these two populations (Figure 4E). Interestingly,
the eight misclassified cases are close to but do not overlap with
the assigned groups, suggesting that unknown clinical condi-
tions, not a problem of the signature, may be responsible for
these misclassifications. It should be noted that these outcome
data were accessed at a 3 year follow-up, and thus the predic-
tion accuracy of this signature will have to be reassessed to
determine whether it can still accurately predict patient survival
and recurrence at longer follow-up periods.
Since several clinical parameters have been shown to corre-
late with HCC prognosis, we further determined whether the
metastatic HCCpredictorwas confoundedby underlying clinical
conditionsbyperformingunivariate andmultivariateCoxpropor-
tional hazards regression analysis. A univariate analysis of vari-
ous clinical variables in the cohort revealed that a-fetoprotein
(AFP), albumin, Child-Pugh score, and several staging systems
(TNM, CLIP, BCLC, and Okuda) were significant predictors of
survival. However, the 17 gene predictor was far superior (a haz-
ard ratio of 9.2) to other clinical variables (hazard ratio of 5.3 or
less) (Table 2). A univariate analysis also revealed that none
of the clinical variables tested were significant predictors of
recurrence; however, the 17 gene predictor was significantly as-
sociated with this outcome (p = 0.001) (Table 2). In the univariate
recurrence analysis, tumor differentiation could not be analyzed
due to the small sample size within this cohort after stratification.
Tumor size was not a significant predictor at either 5 cm or 3 cm
(Table 2 and data not shown). The multivariate Cox regression
model for survival, which controlled for HBV status, ALT,105
A R T I C L EFigure 4. qRT-PCR-based differential expression of signature genes and Th1-like or Th2-like cytokines can distinguish samples with metastatic potential
A: qRT-PCR was conducted on individual noncancerous (NC) samples (n = 8) and MIM (n = 9) or MAM (n = 11) samples. Cytokine or signature gene quantity
was normalized to 18S rRNA and to a normal tissue pool (n = 8). Genes and samples were ordered by Euclidian distance and complete linkage according to
the ratios of abundance in each tissue sample compared to a normal tissue pool (n = 8). Pseudocolors indicate transcript levels above (red), below (green), or
equal to (black) the mean, respectively. The scale represents the gene expression ratios from 7 to 27 in log 2 scale.
B: PAM analysis of MIM (n = 9; pink squares) and MAM (n = 11; blue diamonds) samples used in the training set.
C: PAM analysis of an additional 95 samples (52 MAM and 43 MIM). The 11 samples on the right side of the dotted line within the MIM-defined box represent
those solitary HCC with venous metastases confirmed at follow-up.
D: Kaplan-Meier recurrence or survival analysis of metastatic and nonmetastatic samples based on the results of PAM classification.
E: Multidimensional scaling of training samples (MIM, pink; MAM, light blue) and testing samples (MIM, red; MAM, dark blue; MIM with venous metastases
confirmed at follow-up, yellow) based on Euclidian distance of the expression of the 17 gene signature. Labeled circles represent misclassified samples.Child-Pugh score, microvascular invasion, and tumor differenti-
ation showed a 15.1 increased risk of death for those with the
MIM expression profile compared with that of MAM (Table 2).
Although Child-Pugh score showed a significant association
with death in metastatic compared to nonmetastatic samples
(p = 0.014), the predictor was most significantly associated106with this outcome for samples with the MIM profile (p < 0.001).
A further evaluation of the significant weight of CLIP, BCLC,
and Okuda staging in a multivariate model was not performed
due tomissing data for these covariates (n = 86). Themultivariate
Cox regression model for recurrence which controlled for HBV
status, AFP, and albumin showed a 7.9 increased risk ofCANCER CELL AUGUST 2006
A R T I C L ETable 1. Description of the 17 gene metastasis signature derived from noncancerous hepatic tissues
Gene symbol Gene name Unigene ID Function Source of cells
IL1A interleukin 1, a Hs.1722 activates T and B cells and monocytes T or B cells, monocytes,
macrophages
IL1B interleukin 1, b Hs.126256 activates T and B cells and monocytes T or B cells, monocytes,
macrophages
IL2 interleukin 2 Hs.89679 growth and differentiation of all immune cells T cells
IL12A interleukin 12, p35 Hs.673 stimulates Th1 T cells; induces IFNg; defense against
pathogens
B cells, monocytes,
macrophages
IL12B interleukin 12, p40 Hs.674 stimulates Th1 T cells; induces IFNg; defense against
pathogens
B cells, monocytes,
macrophages
IL15 interleukin 15 Hs.311958 similar to IL-2; stimulates T cell proliferation monocytes
IFNG interferon g Hs.856 monocyte activator; regulates immune and
inflammatory responses
T cells, macrophages,
NK cells
TNF tumor necrosis factor Hs.241570 mediator of inflammatory and immune functions T or B cells, monocytes,
macrophages
IL4 interleukin 4 Hs.73917 induces secretion of Ig by B cells; pleiotropic effect on T cells T or mast cells
IL5 interleukin 5 Hs.2247 differentiation factor for B cells and eosinophils T or mast cells
IL8 interleukin 8 Hs.624 angiogenic factor; activating factor for neutrophil;
attracts basophils
T or B cells, monocytes
IL10 interleukin 10 Hs.193717 blocks Th1 T cells cytokines; stimulates proliferation
of B cells, thymocytes, and mast cells; stimulates IgA
production by B cells
T or B cells, monocytes
CSF1 colony-stimulating
factor
Hs.173894 stimulates the proliferation, differentiation, and
survival of monocytes, macrophages
epithelial cells, fibroblasts,
endothelial cells
ANXA1 annexin A1 Hs.494173 anti-inflammatory, capable of decreasing
leukocyte migration
monocytes, neutrophils
HLA-DRA MHC class II antigen Hs.520048 antigen presentation dendritic, B, epithelial, or
endothelial cells,
macrophages, fibroblasts
HLA-DPA1 MHC class II antigen Hs.347270 antigen presentation dendritic, B, epithelial, or
endothelial cells,
macrophages, fibroblasts
PRG1 platelet proteoglycan Hs.1908 involved in packaging of proteins into secretory
granules and/or directing the secretion of such
molecules as cytokines or chymases
hematopoietic cells,
endothelial cellsrecurrence for those with the MIM expression profile compared
with that of MAM (Table 2). Although HBV status showed a
borderline significant association with death in metastatic com-
pared to nonmetastatic samples (p = 0.053), the MIM-MAM sig-
naturewasa far better predictor of patient recurrence (p<0.001).
These results show that the predictor was by far the strongest
prognosticator for both patient survival and recurrence when
compared to any of the clinical variables analyzed.
Discussion
Amajor hallmark of an aggressive solitaryHCC is its ability tome-
tastasize. Understanding the mechanisms underlying this pro-
cess would allow for the development of effective approaches
to reduce HCC-related mortality. Our recent studies indicate
that the gene expression signature of primary HCCs is very sim-
ilar to that of their corresponding metastases (Ye et al., 2003). In
contrast, the gene expression signature differs significantly be-
tween metastasis-free primary HCCs and HCCs with accompa-
nying intrahepatic metastases (Ye et al., 2003). These results are
consistent with our findings that the HCCmetastasis signature is
independent of tumor size, tumor encapsulation, and patient
age. A recent study on colon cancer metastasizing to the liver
is consistentwith our findings (D’Arrigo et al., 2005). In this study,
we have demonstrated that livers bearing metastatic HCC also
have a significantly different gene expression profile when com-
pared to the livers bearing nonmetastatic HCC, and this differ-
ence is also independent of tumor size. Although these twoCANCER CELL AUGUST 2006signatures are uniquely different, both provide sufficient weight
to predictmetastaticHCCand survival. These results are consis-
tent with the clinical presentations of metastatic HCC patients
who have a propensity to develop intrahepatic metastases
even after a curative resection. Our findings support many pub-
lished studies on tumor and stroma interaction (Mueller and
Fusenig, 2004), which suggest that the metastatic propensity
of HCC both is inherent to the tumor cell and is influenced by
the local environmental status of metastatic sites. Evidence for
tumor influence in cancer progression has been shown in recent
publications demonstrating the influence of tumor-infiltrating
lymphocytes in follicular lymphoma and the role of tumor-edu-
cated macrophages in breast carcinoma (Dave et al., 2004; Pol-
lard, 2004). The microenvironment receptivity of the patients in
this study could therefore be influenced by factors produced
by the neighboring primary HCC tumor. On another token, an in-
dividual’s genetic constitution may also play an important role in
affecting elements of the immune system and generating tumor-
promoting effects (Hunter andCrawford, 2006). In fact,many cy-
tokine polymorphisms are functionally related to HCC. It is pos-
sible that the changes in themicroenvironment inMIM andMAM
cases may be a consequence of differing genetic factors that
dictate HCC metastatic susceptibility. The specific roles of pri-
mary tumors or genetic imbalances in ‘‘priming’’ the receptive-
ness of the liver microenvironment to HCC metastasis remain
to be determined. It should also be noted that the identified pre-
dictor is only applicable at the present time for surgically eligible
HCC patients because only about 20% of HCC patients are107
A R T I C L ETable 2. Univariate and multivariate analyses of factors associated with survival and recurrence
Survival Recurrence
Univariate analysisa Multivariate analysisb Univariate analysis Multivariate analysis
Clinical variable
Hazard ratio
(95% CIc) p value
Hazard ratio
(95% CI) p value
Hazard ratio
(95% CI) p value
Hazard ratio
(95% CI) p value
MIM/MAM predictor (MIM versus MAM) 9.2 (4.2–20.0) <0.001g 15.1 (5.0–45.8) <0.001g 6.2 (2.1–18.8) 0.001g 7.9 (2.5–25.0) <0.001g
Age (R50 year versus <50 year) 1.0 (0.5–1.8) 0.967 n.a.f 0.8 (0.3–1.9) 0.559 n.a.
Sex (male versus female) 3.3 (0.8–13.7) 0.100 n.a. 2.6 (0.4–19.7) 0.100 n.a.
HBV (AVR-CC versus CC)d 0.9 (0.4–2.1) 0.735 0.9 (0.3–2.4) 0.796 2.3 (0.9–5.9) 0.100 3.5 (1.0–12.4) 0.053
AFP (R300 ng/ml versus <300 ng/ml) 2.0 (1.0–3.7) 0.038g n.a. 2.2 (0.9–5.1) 0.102 2.9 (0.8–9.8) 0.089
ALT (R50 U/l versus <50 U/l) 1.0 (0.5–2.0) 0.945 0.6 (0.3–1.4) 0.234 1.0 (0.4–2.4) 0.964 n.a.
Albumin (R0.15 g/l versus >0.15 g/l) 0.3 (0.1–0.6) 0.001g n.a. 1.1 (0.3–3.7) 0.902 1.9 (0.5–6.8) 0.326
Child-Pugh score (B versus A) 2.9 (1.0–8.4) 0.049g 5.2 (1.4–19.1) 0.014g 1.5 (0.4–6.6) 0.581 n.a.
Tumor size (R3 cm versus <3 cm) 2.0 (0.7–5.1) 0.157 n.a. 1.3 (0.4–4.3) 0.711 n.a.
Tumor encapsulation (none versus complete) 2.2 (1.0–4.6) 0.053 n.a. 3.7 (0.7–16.1) 0.079 n.a.
Microvascular invasion (yes versus no) 2.1 (1.1–3.9) 0.024g 1.1 (0.6–2.1) 0.841 2.3 (0.9–6.0) 0.071 n.a.
TNM stage (II + III versus I)e 2.9 (1.4–6.1) 0.024g n.a. 2.8 (0.6–11.9) 0.176 n.a.
CLIP stage (2 + 3 + 4 versus 0 + 1) 5.3 (2.5–11.4) <0.001g n.a. 1.9 (0.7–5.1) 0.186 n.a.
BCLC stage (B + C versus 0 + A) 5.3 (2.4–11.4) <0.001g n.a. 1.8 (0.7–4.8) 0.228 n.a.
Okuda stage (1 versus 0) 2.9 (1.4–6.1) 0.006g n.a. 1.3 (0.4–3.9) 0.664 n.a.
Tumor differentiation (II versus I–II) 0.7 (0.2–2.5) 0.628 1.1 (0.2–8.4) 0.906 n.a. n.a.
Tumor differentiation (II–III + III + IV versus I–II) 1.1 (0.3–3.7) 0.904 2.7 (0.3–26.5) 0.401 n.a. n.a.
aUnivariate analysis, Cox proportional hazards regression.
bMultivariate analysis, Cox proportional hazards regression.
c95% CI, 95% confidence interval.
dCC, chronic carrier; AVR-CC, active viral replication chronic carrier.
eStages II and III were combined because of the presence of vascular invasion at these stages.
fn.a., not applicable.
gSignificant.currently qualified for resection. In addition, due to the predom-
inant HBV+ status of this cohort, it remains to be determined
whether this signature is suitable for HCC patients with other un-
derlying liver diseases such as those related to hepatitis Cand/or
alcohol.
Our results indicate that the hepatic microenvironment from
patients with HBV-positive metastatic HCC have a profound
change in their gene expression profiles. The two significant
clusters in the profile reveal notable changes associated with
genes whose products are involved in immune function. In fact,
over 30% of the genes in these clusters are known to be related
to this process. Moreover, the pro-inflammatory cytokines such
as TNF, IFNG, and IL1 are significantly downregulated while the
anti-inflammatory cytokines such as IL4, IL5, IL8, and IL10 are
highly elevated in livers with metastatic HCC. It is known that
TNF and IFNG are involved in the activation of cytotoxic T lym-
phocytes to induce tumor killing, whereas elevated levels of IL4
and IL10 are reported to be associated with poor prognosis of
cancer (Berghella et al., 2002;Hattori et al., 2003). Consequently,
TNFand IFNGhavebeenused in several clinical trialswithamea-
surable effect onmetastatic tumors (Smythet al., 2004).Our find-
ings that hepatic tissues from metastatic HCC patients have
a global decrease in the production of pro-inflammatory Th1-
like cytokines and amore pronounced global increase in the pro-
duction of anti-inflammatory Th2-like cytokines are consistent
with the hypothesis that a unique immunological profile is acti-
vated to promote HCC metastases. Although many immune
cell types can produce and be activated by cytokines, T cells
are thepredominant cell type involved in this process.Our results
show that the T cell population, assayed by CD3marker expres-
sion, is involved in thepromotionof Th2cytokines and repression
of Th1 cytokines in PBMC induced by CSF1. T cells function in108innate immunity in two distinct types, CD4+ T helper cells and
CD8+ cytotoxic T cells (CTL). Although theCD4+andCD8+pop-
ulations do not seem to differ in number betweenMIM andMAM
samples (data not shown), it is possible that these populations
are differentially primed in prometastatic conditions, in part by
the activity of CSF1, and thus produce cytokine profiles that fa-
vor cancer advancement. The experimental results with T cells,
however, do not rule out the possibility that other CD3-positive
cell populations promote Th2. A NK cell subclass, termed NKT,
that is abundant in the liver and represents approximately 10%
of human PBMC, expresses cell surface markers for T (CD3)
and NK cells (CD56) (Van Dommelen and Degli-Esposti, 2004).
These cells have been implicated in detrimental immune re-
sponses and hepatic injury and could play a role in skewing cy-
tokine responses throughexcessive IL4production (Golden-Ma-
son and Rosen, 2006; Johansson et al., 2006; Johnson et al.,
2002). Moreover, in general, natural killer (NK) cells produce
a range of cytokines and are required to activate CTLs and
CD4+ T cells and thus initiate T cell responses (Zingoni et al.,
2005). Our data show that NK cells are also involved in Th2 pro-
motion in PBMC treatedwith CSF1 (data not shown). Further ex-
periments are warranted to analyze the role of hepatic NK and
NKT cells in the cytokine profile imbalances that occur with ve-
nous metastases.
Inflammation is known to be closely associated with cancer
development (Coussens and Werb, 2002; de Visser and Cous-
sens, 2005;Hussain et al., 2003;Mann et al., 2005). For example,
inflammation can result in an increase in nitric oxide production
byNOS2,which in turn activates a p53-mediated tumor suppres-
sive pathway (Ambs et al., 1998; Hofseth et al., 2003). Thus, the
predominant humoral cytokine response in the liver milieu
suggests that shifts to anti-inflammatory/immune-suppressiveCANCER CELL AUGUST 2006
A R T I C L Eresponses may play a significant role in promoting HCC venous
metastases. This is supported by our observation that the
number of hepatic macrophages are increased in livers bearing
metastatic HCC, which coincides with an increase in HLA-DR-
positive cells and a decrease in NOS2 expression. Our results
show that a CD3-negative population is also involved in CSF1-
induced production of anti-inflammatory Th2 cytokine that may
promote HCC venous metastases. Macrophages can respond
to microenvironmental signals with distinct functional polariza-
tion programs, which regulate the influx of other immune cells,
such as T lymphocytes, by producing a variety of cytokines and
chemokines (Mantovani et al., 2002). Increased evidence indi-
cates that tumor-associated macrophages (TAM) can polarize
toward a type II phenotype, which is oriented toward tissue re-
modeling and repair, a process thatmaybecompatiblewithmet-
astatic progression (Pollard, 2004). Our results indicate that the
Th1 to Th2-like profile switch in livers bearing metastatic HCC
are accompanied by an overexpression of CSF1, as well as
MHCclass II-related genes, andmany other immune cell-related
genes including PRG1 and ANXA1, which are consistent with the
hypothesis that a unique immunological condition regulated by
Kupffer cells may promote HCC metastases. These findings
are reminiscent of the TAM phenotype described above,
whereby macrophages are ‘‘alternatively activated.’’ Consis-
tently, CSF1, an activator and regulator of macrophages, can in-
duce the Th1 to Th2-like profile switch in PBMC from healthy
blood donors. We refer to this unique Th2-like profile associated
with venousmetastasis-susceptible (MS) condition of the liver as
MS-Th2 and theTh1-like profile associatedwith a venousmetas-
tasis-unsusceptible (MU) condition as MU-Th1. Stratifying HCC
patients according to MS-Th2 or MU-Th1 profiles may allow for
better classification of these patients for treatment.
In this study, we have found that the 17 gene signature pro-
vides greater than 92% accuracy in correctly predicting venous
metastases of an independent HCC cohort. Remarkably, this
signature can also predict distantmetastases developed several
years later after resection. The 17 gene expression profile is also
capable of significantly distinguishing patients who are likely to
experience recurrence after curative resection (79% sensitivity).
Althoughwehave already identified a tumor signature capable of
predicting HCC venous metastases, the microenvironmental
signature outweighs the former’s prediction accuracy (78% ver-
sus 93%). Importantly, the immune-related signature can also
predict recurrence and was tested in a much larger cohort than
our former tumor-based HCC predictor and included prediction
tests of independent validation samples. It should be noted,
however, that the tumor signature utilized tumor specimens
that were ground to extract RNA, and hence there may have
been some contribution from themicroenvironment surrounding
thesesamples.However, thiswould represent a small proportion
of the total tumor specimen and therefore would not significantly
overlap with the microenvironment signature presented in this
study. Interestingly, the prognostic markers identified in a recent
microarray study analyzing survival prediction in follicular lym-
phoma do not overlap with microenvironment immune signature
in this study, suggesting that the prognostic genes may differ
among different tumor types (Dave et al., 2004). It should also
be noted that the 17 gene venous metastasis signature was
solely based on qRT-PCR analysis, whereas the HCC tumor sig-
naturewasbasedonmicroarray results. TheqRT-PCRapproach
appears to be superior in accurately predicting an independentCANCER CELL AUGUST 2006cohort of HCC patients with or without metastases when com-
pared to the microarray technique. It is possible that the qRT-
PCR approach provides a better sensitivity and resolution for
molecular classification, which should be recommended for
gene expression-based diagnosis.
The results described in this study may provide a strategy for
classification of patients and potential therapy of metastatic
HCC by converting the unique MIM to a MAM profile. Current
pro-inflammatory-based postoperative therapies to prevent
HCC recurrence show a beneficial effect; however, not all pa-
tients are sensitive to this treatment regimen. We speculate
that postsurgical treatment with IFNG or perhaps other Th1-
related cytokines in the MIM group may ameliorate the meta-
static-related imbalance of cytokines toward that of nonmeta-
static HCC patients. These adjuvant therapies may improve
responses by selecting only the MIM group identified by the 17
gene predictor as those eligible and most likely to benefit from
pro-inflammatory cytokine treatment. Thus, a confident determi-
nationof individualHCCpatientswhohaveeither aMIMprofile or
a MAM may allow us to classify these patients in advance and
thus provide ample time to select the most suitable treatments.
This possibility remains to be determined and could significantly
affect the clinical outcome of patients likely to develop HCC
venous metastases.
Experimental procedures
Clinical specimens
Gene expression profiles were conducted in noncancerous hepatic fresh fro-
zen tissues from 115 Asian HCC patients. Among them, 88% were male,
91% had underlying cirrhosis, and 96% were serologically positive for HBV
(Table S1). Fifty-one percent of patients had a serum a-fetoprotein (AFP)
levelR 300 ng/ml. The average age of this cohort was 50 years. These sam-
ples were categorized into two groups: 52 MIM and 63 MAM (see Supple-
mental Data). MIM (metastasis-inclined microenvironment) refers to hepatic
tissues from patients with primary HCC lesions accompanied by venous me-
tastases found in the portal vein, inferior vena cava, or common bile duct, or
with solitary HCC subsequently having developed distant metastases that
were confirmed at follow-up; MAM (metastasis-averse microenvironment)
refers to hepatic tissues from patients carrying a single HCC lesion with no
detectable metastases at the time of diagnosis and at follow-up. Of the
115 samples, 9 MIM and 11 MAM samples, which were used in our previous
microarray study of HCC tumors, were chosen for the current microarray
study so that a side-by-side comparison of the prognostic signatures from
the tumors and noncancerous regions could be done. Hepatic tissue
samples of 22 chronic liver disease noncancer patients with cirrhosis (AIH,
autoimmune hepatitis [n = 6]; PBC, primary biliary cirrhosis [n = 8]; or HBV,
hepatitis B virus [n = 8]) were also used in this study. In addition, eight normal
liver tissues from disease-free patients whowere liver donors without any de-
tectable HCC or underlying liver conditions such as cirrhosis or dysplasia
were used as a reference control in both microarray and qRT-PCR-based
profiling. Total RNA from 54 hepatic tissue samples (8 normal liver, 22 chronic
liverdiseases, aswell as24HCCpatients [12MIMand12MAM])were fromour
previous studies (Kim et al., 2004; Ye et al., 2003). Total RNA from the addi-
tional 91 HCC hepatic tissues (40 MIM and 51 MAM) were obtained with in-
formed consent from patients who underwent curative resection at the Liver
Cancer Institute andZhongshanHospital (FudanUniversity, Shanghai,China).
The studywas approved by the Institutional Review Board of the Liver Cancer
Institute and NIH. Immunohistochemical analysis of NOS2was conducted on
68 independent paraffin-embedded hepatic tissues (37 MIM and 31 MAM)
from HCC patients obtained from Zhongshan Hospital that were not used
for gene expression profiling studies, except for five MIM and seven MAM.
cDNA microarrays, RNA isolation, and qRT-PCR
The cDNA microarray platform, RNA isolation, and microarray methodology
were essentially as previously described (Ye et al., 2003). The microarray109
A R T I C L Edata have been submitted to the Gene Expression Omnibus (GEO) public
database at NCBI, and the accession number is GSE5093 (GSM114909-
GSM114928). For qRT-PCR, isolated RNA was converted to cDNA using
the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA).
Reactions were performed with the ABI PRISM 7700 Sequence Detector
System (Applied Biosystems) (see Supplemental Data). Human 18S RNA la-
beled with VIC reporter dye was used as an endogenous control. The cyto-
kine expression profiles were quantified by qRT-PCR using the Taqman Cy-
tokine Gene Expression Plate (Applied Biosystems) (see Supplemental Data).
The reproducibility of the 17 gene signature assay was determined in tripli-
cate on three separate plates with normal liver samples, and the standard
deviations for these genes were 0.021 to 0.778.
Statistical analyses
Unsupervised hierarchical clustering analysis was performed by the GENE-
SIS software version 1.5 developed by Alexander Sturn (IBMT-TUG, Graz,
Austria). The BRB ArrayTools software V3.2.2 was also used for supervised
and unsupervised analyses, as described previously (Ye et al., 2003). In the
qRT-PCR-based profiling for class prediction utilizing the 17 gene signature,
we used PAM (prediction analysis of microarrays) developed by Tibshirani
et al. (2002). Multidimensional scaling analysis based on Euclidean distance
was used to visualize the classification outcome of the training and indepen-
dent test cases. The Kaplan-Meier survival analysis was used to compare
patient survival based on prediction results, using Excel-based WinSTAT
software (http://www.winstat.com/). The statistical p value was generated
by the Cox-Mantel log-rank test. Cox proportional hazards regression
(univariate and multivariate tests) was used to analyze the effect of fifteen
clinical variables on patient survival or recurrence using STATA 8.0 (College
Station, TX) (see Supplemental Data). The statistical significance was
defined as p < 0.05.
Immunohistochemistry, ELISA, and PBMC isolation
Immunohistochemical (IHC) staining was performed on 5 mm sections of
paraffin-embedded tissue samples. Anti-NOS2 (BD Transduction Labs, San
Diego, CA), anti-CSF1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
anti-CD45 (BD Pharmingen, San Diego, CA), anti-DR (DakoCytomation, Car-
pinteria, CA), anti-CD68 (AbCAM, Cambridge, MA) were used to detect
NOS2, CSF1, CD45, HLA-DR, and CD68, respectively. Detailed IHC proto-
cols and quantification methods are described in the Supplemental Data.
TheCSF1ELISA assaywas performed onHCCand non-HCCserumsamples
(HBsAg carriers) using the M-CSF Quantikine Kit (R&D Systems, Inc., Minne-
apolis, MN). PBMC was isolated from healthy blood donor buffy coat
(approved and provided by the NIH Department of Transfusion Medicine)
by density-based centrifugation through histopaque (Sigma, St. Louis, MO).
qRT-PCR on the cytokine plate was conducted as described above.
FACS analysis
Immunophenotypic analysis was performed by FACS using FITC-conjugated
monoclonal antibody to CD3 (BD Pharmingen, San Diego, CA) and APC-
conjugated monoclonal antibodies to IFNG or IL4. Freshly isolated human
PBMCs (23 106 cells) were stained using the Cytofix/Cytoperm kit (BD Phar-
mingen, San Diego, CA) according to the manufacturer’s protocol (see Sup-
plemental Data). Cells were acquired by a FACsCalibur (BD Biosciences, San
Diego, CA) using Cell Quest Pro software, and data analysis was performed
using FlowJo software (Version 5.7.2, Tree Star, Inc.).
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
four supplemental figures, and six supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/2/
99/DC1/.
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